Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Thyroid Neoplasms 1Melanoma 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignancies 1

Interventions

Specimen Handling 51pembrolizumab 46Magnetic Resonance Spectroscopy 38Biopsy 37Cyclophosphamide 34fludarabine 29Cetuximab 20Cisplatin 19Carboplatin 19Radiotherapy 16Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Nivolumab 14Fluorouracil 14fludarabine phosphate 13Leucovorin 13Gemcitabine 13Temozolomide 11Pemetrexed 11Oxaliplatin 11Cytarabine 11Paclitaxel 10Irinotecan 10Ipilimumab 10130-nm albumin-bound paclitaxel 10Prednisone 9Immunoglobulin G 9Fulvestrant 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Midazolam × 30 days × Clear all
NCT05355701 2026-06-05

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pfizer

Phase 1 Recruiting
267 enrolled
CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT07426757 2026-06-01

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Pfizer

Phase 1 Recruiting
120 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡